| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/13/2010 | US7695725 also comprises nucleic acid molecule (modified by contact with a psoralen activated by ultraviolet radiation) encoding non-Listerial antigen; immunogens; antigen presenting cells |
| 04/13/2010 | US7695724 Recombinant rabies virus compositions |
| 04/13/2010 | US7695721 Gonadotrophins in the treatment anovulatory women |
| 04/13/2010 | US7695720 target VEGFR2 (KDR/flk-1); for treating and preventing tumors |
| 04/13/2010 | US7695718 Methods for the treatment of IL-1β related diseases |
| 04/13/2010 | US7695717 Method of treating an IL-1 related inflammatory disease or condition |
| 04/13/2010 | US7695716 Using CD33 specific monoclonal antibody to treat and prevent acute myeloid leukemia and myelodysplastic syndromes |
| 04/13/2010 | US7695715 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases |
| 04/13/2010 | US7695713 Isolation and identification of T cells |
| 04/13/2010 | US7695697 Devices for crude oil treatment and upgrading |
| 04/13/2010 | CA2449747C Use of fkbp chaperones as expression tool |
| 04/13/2010 | CA2386863C Antigenic modification of polypeptides |
| 04/13/2010 | CA2330206C Poly(adp-ribose) polymerase gene |
| 04/13/2010 | CA2265500C Novel semaphorin gene: semaphorin y |
| 04/13/2010 | CA2257357C Humanized antibodies with modified glycosylation |
| 04/13/2010 | CA2244946C Gene expression vectors which generate an antigen specific immune response and methods of using the same |
| 04/13/2010 | CA2224003C Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell |
| 04/13/2010 | CA2200868C Cdr-grafted type iii anti-cea humanized mouse monoclonal antibodies |
| 04/13/2010 | CA2189015C Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases |
| 04/13/2010 | CA2153593C Compositions and methods for delivery of genetic material |
| 04/13/2010 | CA2144056C Cd27 ligand |
| 04/13/2010 | CA2089229C Cd40cr receptor and ligands therefor |
| 04/13/2010 | CA2077154C Hcmv-specific peptides, agents therefor and the use thereof |
| 04/11/2010 | WO2010126137A1 Anti-cadherin antibody |
| 04/08/2010 | WO2010040136A2 Selection of hiv vaccine antigens by use of intrapatient sequence variation to identify mutations in the hiv envelope glycoprotein that affect the binding of broadly neutralizing antibodies |
| 04/08/2010 | WO2010040135A1 Compositions comprising hmw-maa and fragments thereof, and methods of use thereof |
| 04/08/2010 | WO2010040096A2 Methods for the treatment of graft-versus-host disease |
| 04/08/2010 | WO2010040054A2 Methods for suppressing toll-like receptor activity |
| 04/08/2010 | WO2010040033A2 Methods and compositions for modulating an immune response with immunogenic oligonucleotides |
| 04/08/2010 | WO2010040001A1 New hcv entry factor, occludin |
| 04/08/2010 | WO2010040000A2 A multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia |
| 04/08/2010 | WO2010039934A1 Bovine herpes virus -1 compositions, vaccines and methods |
| 04/08/2010 | WO2010039900A2 Non-human mammals for the production of chimeric antibodies |
| 04/08/2010 | WO2010039832A1 Anti-notch2 antibodies and methods of use |
| 04/08/2010 | WO2010039801A2 Methods of treating hepatitis c virus infection |
| 04/08/2010 | WO2010039742A2 Methods to reduce b-helper t cells to treat autoimmune diseases |
| 04/08/2010 | WO2010039563A2 Protective vaccine against staphylococcus aureus biofilms comprising cell wall-associated immunogens |
| 04/08/2010 | WO2010039248A1 Methods for the treatment of cancer |
| 04/08/2010 | WO2010039224A2 Respiratory syncytial virus (rsv) sequences for protein expression and vaccines |
| 04/08/2010 | WO2010039223A2 T-cell immunogens derived from anti-viral proteins and methods of using same |
| 04/08/2010 | WO2010039154A1 Hepatitis c antibodies and uses thereof |
| 04/08/2010 | WO2010039049A1 Method of modifying the immune response |
| 04/08/2010 | WO2010038840A1 METHOD FOR PREDICTING PHARMACOLOGICAL EFFICACY OF ANTI-TNFα ANTIBODY PREPARATION ON RHEUMATOID ARTHRITIS, AND PHARMACOLOGICAL EFFICACY PREDICTION APPARATUS |
| 04/08/2010 | WO2010038719A1 Method for producing purified influenza virus antigen |
| 04/08/2010 | WO2010038076A1 Anthrax vaccine formulation and uses thereof |
| 04/08/2010 | WO2010038035A1 Carrier |
| 04/08/2010 | WO2010037539A1 Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| 04/08/2010 | WO2010037514A2 Novel immunotherapy against several tumors including neuronal and brain tumors |
| 04/08/2010 | WO2010037513A1 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers |
| 04/08/2010 | WO2010037408A1 Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| 04/08/2010 | WO2010037403A1 Hepatitis c virus expressing reporter tagged ns5a protein |
| 04/08/2010 | WO2010037402A1 Molecular vaccines for infectious disease |
| 04/08/2010 | WO2010037395A2 Mhc multimers in cancer vaccines and immune monitoring |
| 04/08/2010 | WO2010037352A1 Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormone (gnrh) as immunogen |
| 04/08/2010 | WO2010019890A3 Vaccine for shigella |
| 04/08/2010 | WO2009158432A3 Ang-2 inhibition to treat multiple sclerosis |
| 04/08/2010 | WO2009155886A3 Ferritin 2 for the host immunization against ticks |
| 04/08/2010 | WO2009155504A9 Methods for the modulation of angiogenesis |
| 04/08/2010 | WO2009135019A3 Methods and compositions for prostate cancer immunotherapy |
| 04/08/2010 | WO2009128950A3 Deletion mutants of flagellin and methods of use |
| 04/08/2010 | WO2008152537A3 Humanized monoclonal antibodies |
| 04/08/2010 | US20100088778 Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene |
| 04/08/2010 | US20100088775 Methods of modulating epithelial-mesenchymal transition and mesenchymal-epithelial transition in cells and agents useful for the same |
| 04/08/2010 | US20100088774 Characterization of granulocytic ehrlichia and methods of use |
| 04/08/2010 | US20100087621 Immune reactivity to her-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is associated |
| 04/08/2010 | US20100087510 Novel Adaptor protein that binds to mammalian toll-like receptor 3 and gene thereof |
| 04/08/2010 | US20100087373 Detection and therapy of bacterial infection caused by enterobacteriaceae |
| 04/08/2010 | US20100087001 Anti-angiogenic cellular agent for cancer therapy |
| 04/08/2010 | US20100086995 Mhc class i peptide epitopes from the human 5t4 tumor-associated antigen |
| 04/08/2010 | US20100086985 Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer |
| 04/08/2010 | US20100086942 Compounds |
| 04/08/2010 | US20100086585 Antinuclear antibody utilized as a targeting agent for pharmaceutical compounds used in the treatment of cancer and other diseases |
| 04/08/2010 | US20100086584 VACCINE COMPOSITIONS OF M2e, HA0 AND BM2 MULTIPLE ANTIGENIC PEPTIDES |
| 04/08/2010 | US20100086579 Macrocyclic lactone compounds and methods for their use |
| 04/08/2010 | US20100086571 Methods to decrease the risk of metabolic syndrome post immunization |
| 04/08/2010 | US20100086570 Cancer immunotherapy predictive parameters |
| 04/08/2010 | US20100086569 Use of a first house dust mite group 2 allergen for treating allergy to a second house dust mite group 2 allergen |
| 04/08/2010 | US20100086568 Modification of allergens |
| 04/08/2010 | US20100086567 Botulinum toxin therapy for prevention of anastamotic thrombosis in free tissue transfer |
| 04/08/2010 | US20100086566 Hiv administration protocols |
| 04/08/2010 | US20100086565 Vectors for expression of hml-2 polypeptides |
| 04/08/2010 | US20100086564 West Nile Virus Vaccine |
| 04/08/2010 | US20100086563 Compositions and Methods for Detection of Antibodies Specific for Anaplasma phagocytophilum (Aph) and Anaplasma platys (Apl) |
| 04/08/2010 | US20100086562 Use of Platelet Glycopeptide IIIA Epitopes in the Treatment of Immune Thrombocytopenic Purpura |
| 04/08/2010 | US20100086561 Th1 vaccination priming for active immunotherapy |
| 04/08/2010 | US20100086560 Chemokines as adjuvants of immune response |
| 04/08/2010 | US20100086559 Polypeptide formulation |
| 04/08/2010 | US20100086558 isolated from Coprinus clastophyllus; for treating celiac disease caused by proline abundant gluten |
| 04/08/2010 | US20100086557 Pharmaceutical composition for tumor treatment |
| 04/08/2010 | US20100086556 Use of hemagglutinin of the african swine fever virus as an adjuvant |
| 04/08/2010 | US20100086555 Neutralizing anti-influenza a virus antibodies and uses thereof |
| 04/08/2010 | US20100086554 Methods for administering anti-il-5 antibodies |
| 04/08/2010 | US20100086553 Antitumor agent |
| 04/08/2010 | US20100086552 Allergen-binding ige monoclonal antibodies and method for preparing hypoallergens |
| 04/08/2010 | US20100086551 Antibody and uses thereof |
| 04/08/2010 | US20100086550 Anticancer agent comprising anti-pd-1 antibody or anti-pd-l1 antibody |
| 04/08/2010 | US20100086549 Use of Anti-IL-20 Antibody for Treating Stroke |
| 04/08/2010 | US20100086548 Use of Anti-IL-20 Antibody for Treating Rheumatoid Arthritis and Osteoporosis |
| 04/08/2010 | US20100086547 Methods for administering anti-il-5 antibodies |
| 04/08/2010 | US20100086546 Toll-LIke Receptor 4 Deficiency and Downstream Effectors Cause Pulmonary Emphysema |